- Home
- SGLY vs LIXT Comparison
SGLY vs LIXT Comparison
Compare SGLY & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- LIXT
- Stock Information
- Founded
- SGLY 2001
- LIXT 2005
- Country
- SGLY United States
- LIXT United States
- Employees
- SGLY N/A
- LIXT N/A
- Industry
- SGLY
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- LIXT Health Care
- Exchange
- SGLY Nasdaq
- LIXT Nasdaq
- Market Cap
- SGLY 4.0M
- LIXT 12.4M
- IPO Year
- SGLY 2008
- LIXT N/A
- Fundamental
- Price
- SGLY $1.07
- LIXT $3.41
- Analyst Decision
- SGLY
- LIXT
- Analyst Count
- SGLY 0
- LIXT 0
- Target Price
- SGLY N/A
- LIXT N/A
- AVG Volume (30 Days)
- SGLY 21.3K
- LIXT 136.6K
- Earning Date
- SGLY 09-02-2025
- LIXT 08-07-2025
- Dividend Yield
- SGLY N/A
- LIXT N/A
- EPS Growth
- SGLY N/A
- LIXT N/A
- EPS
- SGLY N/A
- LIXT N/A
- Revenue
- SGLY $2,172,036.00
- LIXT N/A
- Revenue This Year
- SGLY N/A
- LIXT N/A
- Revenue Next Year
- SGLY N/A
- LIXT N/A
- P/E Ratio
- SGLY N/A
- LIXT N/A
- Revenue Growth
- SGLY N/A
- LIXT N/A
- 52 Week Low
- SGLY $0.54
- LIXT $0.64
- 52 Week High
- SGLY $7.65
- LIXT $5.14
- Technical
- Relative Strength Index (RSI)
- SGLY 58.38
- LIXT 44.33
- Support Level
- SGLY $0.91
- LIXT $3.13
- Resistance Level
- SGLY $1.17
- LIXT $4.04
- Average True Range (ATR)
- SGLY 0.06
- LIXT 0.57
- MACD
- SGLY 0.01
- LIXT -0.22
- Stochastic Oscillator
- SGLY 61.54
- LIXT 16.66
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.